Highlights
- Pro Medicus Limited (ASX:PME) generated AUD 261.7 million in FY26 revenue.
- Underlying net profit after tax increased 24.1% to AUD 144.7 million.
- Ten new contracts carried minimum combined value of AUD 407 million.
- Cash and other financial Assets reached AUD 252.3 million, with no debt.
Pro Medicus Limited provides medical imaging software for hospitals, diagnostic imaging networks and radiology practices. The stock (ASX:PME) was trading at AUD 201.61 on November 17, 2026, edging down 0.03% during the session. Its FY26 report combined higher underlying Earnings with a series of enterprise imaging contracts and implementation milestones.
Enterprise Imaging and Software Products
Pro Medicus develops and supplies software for medical imaging, including products distributed through its Visage Imaging operations. Its technology supports viewing, workflow and archival functions for healthcare providers, alongside radiology information systems. Customers include hospitals, health networks and radiology practices across different regions, making deployment requirements and contract duration important commercial characteristics.
New Contracts, Renewals and Deployments
The FY26 results disclosed ten new contracts with a minimum combined value of AUD 407 million. These included a ten-year AUD 170 million agreement with UCHealth Colorado and a seven-year AUD 90 million agreement with Beth Israel Lahey Health. The company also renewed all six contracts due for renewal during the period, with a combined value of AUD 141 million on five-year terms.
Sixteen implementations were completed during FY26, including stages of the Trinity Health programme and deployments at other health systems. Management stated that the Trinity implementation was largely complete, with full-year contribution expected in FY27. Pro Medicus Limited (ASX:PME) also introduced digital pathology and artificial-intelligence-optimised reporting products, broadening its software offerings without establishing any guaranteed Revenue contribution from new features.
FY26 Financial Performance and Accounting Distinctions
Reported FY26 revenue rose 22.9% to AUD 261.7 million. Underlying earnings before interest and tax increased 24.4% to AUD 196.1 million, corresponding to a 74.9% EBIT margin. Underlying net profit after tax was AUD 144.7 million, an increase of 24.1%. The reported net profit figure was materially higher at AUD 265.3 million, reflecting fair-value movements that require separate consideration.
On a constant-currency basis, underlying revenue was AUD 273.5 million, up 28.4%, while underlying EBIT reached AUD 206 million. Constant-currency underlying net profit after tax was AUD 154.5 million, up 32.5%. Those measures help distinguish underlying commercial changes from exchange-rate movements, but should not be substituted for reported accounting figures without explanation.
The Balance Sheet included AUD 252.3 million in cash and other financial assets, and the company reported no debt. Its fully franked final Dividend was 37 Australian cents per share, taking FY26 dividends to 69 cents. Pro Medicus Limited (ASX:PME) remains sensitive to contract implementation schedules even with significant cash resources and contracted relationships.
Imaging Market and Implementation Factors
Diagnostic imaging providers manage increasingly complex image datasets and workflows. The company's technology addresses clinical viewing, archives and related processes, but procurement in health systems can involve extended evaluations and integration. Deployments across large organisations require coordination with existing applications, clinicians and information-technology teams.
Risks and Monitoring Points
Relevant risks include delayed deployments, customer contract decisions, currency movements, system integration and the accounting effects of fair-value investments. Reported profit may move differently from underlying operating profit when Investment valuations change. Healthcare technology also operates within security, privacy and regulatory constraints.
FY27 updates can show the contribution from completed implementations, progress on newly signed contracts and Demand for Visage products across radiology and cardiology. Renewals, Margin and cash balances remain measurable factors for Pro Medicus Limited (ASX:PME).
Key Insights
FY26 combined increased Operating Revenue with a large contracted implementation pipeline and a debt-free balance sheet. Distinguishing underlying earnings from reported fair-value effects is essential to interpreting the results. Future disclosures will show how deployments and newer product capabilities contribute to recurring operations.






Please wait processing your request...